DXM, CYP2D6-Inhibiting Antidepressants, Piracetam, and Glutamine: Proposing a Ketamine-Class Antidepressant Regimen with Existing Drugs

Rapid-acting antidepressants can lift mood within hours by shifting glutamatergic circuits from an NMDA-dominant to an AMPA-dominant state. Intravenous ketamine achieves this but has dissociative side effects and logistical challenges; the oral combination dextromethorphan + bupropion (Auvelity) only provides initial NMDA blockade, yielding slower, less durable benefit. A proposed fully oral, low-cost, four-component regimen aims to replicate ketamine's plasticity cascade: dextromethorphan for fast NMDA antagonism, a strong CYP2D6 inhibitor to prolong DXM exposure, the AMPA positive allosteric modulator piracetam to amplify downstream glutamate burst, and micronized L-glutamine to restore presynaptic glutamate pools and buffer against excitotoxicity. Preclinical evidence suggests each element synergizes along the same mechanistic axis, potentially democratizing ketamine-level efficacy with inexpensive medications.

Study at a glance

Abstract

Rapid‐acting antidepressants show that mood can lift within hours when glutamatergic circuits are pushed from an "NMDA-dominant" to an "AMPA-dominant" state. Intravenous ketamine achieves this flip but is hampered by dissociative side-effects and clinical logistics, while the oral pairing of dextromethorphan + bupropion (Auvelity®) delivers only the initial NMDA blockade and therefore yields slower, less durable benefit. We propose a fully oral, low-cost, four-component regimen designed to replicate ketamine's entire plasticity cascade: (1) dextromethorphan (DXM) supplies fast NMDA antagonism; (2) a strong CYP2D6 inhibitor (fluoxetine, paroxetine, or high-dose duloxetine) prolongs DXM exposure without relying on bupropion; (3) the AMPA positive allosteric modulator piracetam amplifies the downstream glutamate burst, driving BDNF- and mTOR-dependent synaptogenesis; and (4) micronized L-glutamine restores presynaptic glutamate pools and buffers against excitotoxicity. Preclinical evidence shows that each element—DXM's ketamine-like behavioral effects, piracetam's enhancement of AMPA currents, and glutamine's reversal of stress-induced glutamatergic depletion—synergizes along the same mechanistic axis. This strategy could democratize ketamine-level efficacy using inexpensive, readily available medications.